Press release content from Business Wire. The AP news staff was not involved in its creation.
ISG to Examine Global Enterprise Application-as-a-Service Market
February 19, 2021 GMT
STAMFORD, Conn. (BUSINESS WIRE) Feb 19, 2021
Information Services Group ( ISG ) (Nasdaq: III ), a leading global technology research and advisory firm, has launched a research study examining providers of enterprise application-as-a-service platforms.
ADVERTISEMENT
The study results will be published in a comprehensive ISG Provider Lens
™ report, called Enterprise Application-as-a-Service Platforms, scheduled to be released in July. The report will cover providers of cloud-based human capital management software, enterprise resource planning software and customer relationship management software.
Zielvorgabe Krieg | Unsere Zeit
unsere-zeit.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from unsere-zeit.de Daily Mail and Mail on Sunday newspapers.
Kaliningrad als Zielscheibe | Unsere Zeit
unsere-zeit.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from unsere-zeit.de Daily Mail and Mail on Sunday newspapers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
February 1, 2021 GMT
Clover LOGO (PRNewsfoto/三叶草生物制药有限公司)
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021
CHENGDU, China, Feb. 1, 2021 /PRNewswire/ Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced that the data from its Phase 1 clinical trial evaluating the safety and immunogenicity of its